LATEST ALERTS
Juul Labs has submitted a premarket tobacco product application (PMTA) for the company’s next-generation vapour platform to the US Food and Drug Administration (FDA).
The PMTA includes new evidence from the UK on how the device can aid smoking cessation, as well as data and specifications around preventing youth usage of the device, which will use only new tobacco-flavoured pods at 18 mg/ml nicotine concentration.
...Are you already a subscriber? login here
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.
